Home>Topics>Stocks>Lexicon Pharmaceuticals

Lexicon Pharmaceuticals LXRX

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Morningstar's Most Popular


      Fri, 19 Sep 2014

      Revisite d Most Requested Stock Quotes Apple IBM General Electric AT&T Exxon Mobil Most Requested Stock Analyses Lexicon Pharmaceuticals Apple HCP Rayonier Advanced Materials Apollo Global Management Most Requested Fund Quotes Vanguard Dividend

    2. Lexicon Pharmaceuticals' CEO Presents at Morgan Stanley Healthcare Conference (Transcript)


      Tue, 9 Sep 2014

      By SA Transcripts : Lexicon Pharmaceuticals , Inc. (NASDAQ: LXRX ) Morgan Stanley Healthcare Conference Call September 9, 2014 10:35 AM ET Executives Lonnel Coats – President and Chief Executive

    3. For Lexicon Pharmaceuticals , No News Remains Bad News


      Mon, 11 Aug 2014

      By Stephen Simpson, CFA : The frustrating wait for the key driver at Lexicon Pharmaceuticals (NASDAQ: LXRX ) - a clinical development and marketing partner for LX4211 - goes on. While management spent a lot of time on its earnings call

    4. Lexicon Pharmaceuticals' ( LXRX ) CEO Lonnel Coats on Q2 2014 Results - Earnings Call Transcript


      Sun, 10 Aug 2014

      Lexicon Pharmaceuticals , Inc. (NASDAQ: LXRX ) Q2 2014 Results Earnings Conference Call August 7 ..... this time, I would like to welcome everyone to the Lexicon Pharmaceuticals ’ Second Quarter Earnings Conference Call. All lines

    5. New Morningstar Analyst Report for Lexicon Pharmaceuticals Inc

      Stock Reports

      Fri, 8 Aug 2014

      background in cardiovascular disease and endocrinology, which is critical for the firm's LX4211 program. Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising

    6. More on Lexicon Pharma Q2 results


      Thu, 7 Aug 2014

      Lexicon Pharmaceuticals ( LXRX -3.6% ) Q2 results : Revenues: $676K (+215.9%); Operating Expenses: $26.8M (-7.1%); Operating Loss

    7. Lexicon Pharmaceuticals EPS in-line, beats on revenue


      Thu, 7 Aug 2014

      Lexicon Pharmaceuticals (NASDAQ: LXRX ): Q2 EPS of -$0.05 in-line. Revenue of $0.7M (+233.3% Y/Y) beats by $0.58M . Press Release Post your comment!

    8. Morning Star Ratings


      Wed, 7 May 2014

      I guess I should address this to Morning Star but don't find a way. My question is how can you cover in analysis a stock such as LXRX with 149 employes and not cover in your analysis a stock such as HLS, makes me wonder about how you pick your stocks to analyse. Jack

    9. lxrx not for now.


      Fri, 4 Apr 2014

      Despite a pipeline, lexicon pharma does not look cheap. At a valuation today of nearly 900 million, and an expensive road to drug approval, we should all expect continuing dilution of this equity. To my mind, the only reason to invest is for a catalyst gap up. Their diabetes drug looks intriguing,

    10. M* 5 Star Stocks


      Sat, 22 Mar 2014

      the criterion of "5 stars." I only got 6 stocks, none of them were familiar to me. Can this be right? Alumina AWCMY Buenaventure Mining BVN Fiat Group FIATY Lexicon Pharmaceuticals LXRX Petroleo Brasileiro SA Petrobras ADR BPR Posco PKX

    « Prev1234Next »
    Content Partners